Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

SEATTLE, Wash., Nov. 7, 2013 /PRNewswire/ --

  • Received $17.4 million in cash in October 2013
  • Total operating expenses in 3Q 2013 were $13.6 million including $3.2 million in non-cash expenses compared to $13.3 million including non-cash expenses of $2.1 million in 2Q 2013
  • U.S. and European regulators accepted Omeros' OMS302 marketing applications for review
  • OMS824 and OMS721 Phase 1 clinical programs generated positive data
  • Increased the number of unlocked orphan GPCRs to 52
  • Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2013.

    "Throughout the third quarter of 2013, we continued to make significant strides in development across our pipeline," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "For OMS302, the marketing applications were accepted for review by both the FDA and EMA, and the market launch is planned for the second half of 2014. Our OMS824 program for the treatment of cognitive disorders was granted orphan drug designation by the FDA, generated positive Phase 1 clinical trial results, began enrollment in a Phase 2 trial in patients with schizophrenia and is now initiating a Phase 2 trial in Huntington's disease. OMS721, our MASP-2 inhibitor, entered a Phase 1 clinical trial from which we reported positive data today, and a Phase 2 trial to evaluate the molecule's efficacy and safety in patients with thrombotic microangiopathies is planned for early 2014. Preclinically, our GPCR platform continued to identify functionally active compounds against an
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... Md. (PRWEB) September 17, 2014 ... Comprehensive Two-Dimensional Liquid Chromatograph (2D-LC), which offers ... complex sample matrices. The system provides a ... sample analytes, which is beneficial to scientists ... extracts, and natural products. , Comprehensive 2D-LC ...
    (Date:9/17/2014)... PA & Rockville, MD (PRWEB) September 17, 2014 ... won a Small Business Innovation Research (SBIR) grant to ... immunotherapy. The award will provide ITI with approximately $255,000 ... Tree nuts, a leading cause of food allergy, affect ... cause of anaphylaxis behind peanut allergy. Tree nut exposure ...
    (Date:9/17/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), ... technologies and products for advanced microarray diagnostics, today announced ... in the United States on ... on September 17, 2014 on the OTCQX under the ... the TSX Venture Exchange under its existing symbol SQD. ...
    (Date:9/17/2014)... Escape Alert, LLC . filed international patents ... alert owners if their pet has escaped and enable them to ... in the pet’s body. This is the first implantable microchip ... been around for many years, they are passive until read by ... a pet’s location or alert the owner that the pet has ...
    Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
    ... DENVER, Nov. 8, 2011 Quest Diagnostics joined the ... participate in the American Cancer Society,s historic Cancer Prevention ... this national, longitudinal study is between November 8 and ... lifestyle, environmental and genetic factors that influence cancer risk ...
    ... VIENNA, November 8, 2011 Santo VC ... AFFiRiS AG   effective immediately and has also secured an ... same time, the German MIG fund increased its existing investment ... fund. As a result, AFFiRiS now has an additional EUR ...
    ... Biotech, Inc. (a suburban Philadelphia-based Company) announced today, at ... brand name of its flagship product to "RENADYL™." Formerly ... probiotic formulation helps maintain healthy kidney function. At a ... and health benefits of probiotics, Kibow has opted for ...
    Cached Biology Technology:Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th 2Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th 3AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board 2AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board 3AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board 4Kibow Changes Name of Flagship Kidney Function Support Product to 'RENADYL™' 2
    (Date:9/16/2014)... on September 13, 2014. The fire is human-caused and ... 2,300 acres in size and is mostly being fueled ... calm Monday night due to higher humidity. Yesterday ... beginning to construct a fireline on the West and North ... on the fire: , 7 20-person Crews, 4 Hot Shot ...
    (Date:9/16/2014)... of rock hit the Yukatan peninsula near the site of ... teratons of TNT. It left a crater more than 150 ... volcanism are widely accepted to have wiped out the dinosaurs ... what happened to the plants on which the dinosaurs fed? ... of Arizona reveals that the meteorite impact that spelled doom ...
    (Date:9/16/2014)... votes for independence later this week, its Government could ... that fracking is necessary, research has revealed. , The ... public perception of shale gas extraction in the UK ... north of the border are the least supportive of ... in the University,s School of Geography, said: "The clear ...
    Breaking Biology News(10 mins):Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3Scottish people most sceptical on fracking, survey shows 2Scottish people most sceptical on fracking, survey shows 3
    ... in their own interests and do not cooperate ... severity of infection. The selfish behaviour ... treat antibiotic-resistant infections, according to research being presented ... today. Bacteria work together by using a ...
    ... TORONTO, ON - Widespread reports of a decline in the ... and speculation that pollination is also likely on the decline. ... long-term evidence of a downward trend in pollination, while also ... numbers may have declined at our research site, but we ...
    ... San Diego have discovered that a gene critical for programmed ... stem cells, a finding that could help to improve the ... chemotherapy or radiation therapy that kills cancer cells by inducing ... side effects for human cancer patients is the depletion of ...
    Cached Biology News:Backstabbing bacteria: A new treatment for infection? 2Biologists find way to reduce stem cell loss during cancer treatment 2
    ... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
    ... PrecisION Ion Channel Cell Lines ,High ... ,Ion channels are well known for having ... function and consequently have a key function ... that modulate ion channels have been investigated ...
    ... PrecisION Ion Channel Cell Lines ,High ... ,Ion channels are well known for having ... function and consequently have a key function ... that modulate ion channels have been investigated ...
    Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
    Biology Products: